[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acromegaly-due-to-pituitary-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acromegaly-due-to-pituitary-adenoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100616493","ultrasound-in-predicting-difficult-intubation-in-acromegaly-patients-100616493",false,"NCT07306325","Ultrasound in Predicting Difficult Intubation in Acromegaly Patients","Effectiveness of Ultrasonography in Evaluating the Airway and Predicting Difficult Intubation in Patients Diagnosed With Acromegaly","Inclusion Criteria:\n\n* • Patients diagnosed with acromegaly who are planned for endoscopic pituitary surgery\n\n  * Volunteer participants\n  * American Society of Anesthesiology - ASA 1, 2 and 3 patient groups\n  * Patients with BMI\\\u003C40\n\nExclusion Criteria:\n\n* ASA 4 patient group\n\n  * History of previous neck surgery\n  * Patients with a history of tracheostomy\n  * Patients with a history of radiotherapy to the neck area\n  * Patients with limited neck extension (rheumatological - traumatic reasons)\n  * Patients with masses and lesions in the mouth and airway that may make intubation difficult.","ALL","18 Years","70 Years",{"count":20,"type":21},34,"ESTIMATED","OBSERVATIONAL","This is a prospective observational study.The purpose of this study is to predict difficult intubation with ultrasonographic evaluation combined with preoperative physical examination in patients diagnosed with acromegaly and planned for pituitary surgery.",[25,26,27],"Acromegaly Due to Pituitary Adenoma","Difficult Intubation","Airway Ultrasonography",[29,30,31],"difficult intubation","acromegaly","airway ultrasonography","NOT_YET_RECRUITING","2025-12-13",{"date":35,"type":36},"2025-12-29","ACTUAL",{"date":38,"type":21},"2025-12-25",{"date":40,"type":21},"2026-03-20",{"name":42,"class":43},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":44},"100606774","effects-of-pasireotide-lar-therapy-on-bone-metabolism-100606774","NCT07179926","Effects of Pasireotide Lar Therapy on Bone Metabolism","Pasi-Bone","INCLUSION CRITERIA FOR THE PROSPECTIVE COHORT\n\n* adult patients (\\>18 years)\n* acromegaly not-controlled after 6 months of treatment with fg-SRLs and switched since at least one week, to Pasireotide LAR, according to clinical practice and actual experts consensus,\n* signing of informed consent\n\nINCLUSION CRITERIA FOR THE RETROSPECTIVE COHORT\n\n* adult patients (\\>18 years)\n* acromegaly not-controlled after 6 months of treatment with fg-SRLs and switched to Pegvisomant, according to clinical practice and actual experts' consensus,\n* signing of informed consent or substitute declaration on the consent form where applicable.\n\nExclusion Criteria:\n\n* patients under the age of 18 years.",{"count":53,"type":21},120,"Acromegaly, a chronic condition characterized by growth hormone (GH) and, in turn, insulin-like growth factor-1 (IGF-I) excess, is burdened by a series of systemic and metabolic comorbidities that strongly impair quality of life (QoL) and life expectancy. Amongst them, a specific acromegalic osteopathy has been discovered, characterized by fragility fractures associated with high bone turnover, which need to be early detected, according to most recent guidelines, since they are very frequent and related to chronic pain and reduced QoL. Morphometric vertebral fractures (VFs) are an emerging landmark of skeletal fragility in general population as well as in clinical trials, and are highly prevalent in acromegaly, being reported to affect from 30 up to 60% of patients and represent an early and common event in disease history. Until now, same groups of patients with higher risk of vertebral fractures were identified, such as those carrying incident vertebral fractures, or affected by biochemical active acromegaly, concomitant hypogonadism, or diabetes mellitus. The main aim in the management of patients with acromegaly is to normalize IGF-I levels and restore acromegaly related symptoms. To aim this treatment objective, the first line of treatment of acromegaly, when feasible, is neurosurgery. In cases where surgical intervention fails to achieve biochemical control, medical therapy is recommended, with the objective of reaching normal levels of IGF-1 and GH age-corrected. Octreotide LAR and Lanreotide are the first-line medical therapy. In patients who have not achieved adequate control with standard doses of octreotide LAR and Lanreotide, increasing the dose and\u002For frequency of administration can lead to improved biochemical control. In patients who are unable to achieve control even with this approach, a switch to Pasireotide LAR may be considered. In instances where patients fail to achieve biochemical control with maximal doses of SRL, or in the presence of contraindications, the use of Pegvisomant as a second-line therapy may be considered. In addition, a combination of Pegvisomant and SRL represents a potential avenue for treating patients. Prevention of VFs in acromegaly remains an open issue. It has been shown that use of GH\u002FIGF-I lowering treatments with first-generation SSA and Pegvisomant, may reduce the risk of VFs, while improving disease control. Moreover, in a retrospective and observational multicenter study, it was recently proved that patients treated with second generation SRLs (Pasireotide-LAR) developed less frequently VFs then patients treated with Pegvisomant.",[25,56],"Acromegaly","RECRUITING","2025-09-11",{"date":60,"type":36},"2025-09-18",{"date":62,"type":36},"2025-09-08",{"date":64,"type":21},"2028-06",{"name":66,"class":67},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100589090","ketogenic-diet-therapy-in-patients-with-acromegaly-100589090","NCT06949891","KETOgenic Diet Therapy in Patients With ACROmegaly","Ketogenic Diet Therapy in Patients With Acromegaly","KETOACRO","Inclusion Criteria:\n\n* Male or female, 18 years or older\n* Diagnosis of acromegaly based on elevated GH and\u002For IGF-I levels due to a pituitary tumor\n* IGF-I levels above 80% upper limit of the normal range (xULN)) on a stable medication dose for at least 4 months\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Pegvisomant treatment\n* Has undergone pituitary surgery or radiotherapy within 6 months prior to s study entry;\n* It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study;\n* History or presence of epilepsy;\n* Participation in a trail of an experimental drug or device within 30 days prior to screening;\n* Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study\n* Screening HbA1c \\> 6,5%;\n* Use of antidiabetic medication other than Metformin",{"count":77,"type":21},60,"INTERVENTIONAL",[80],"NA","Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH). Symptoms caused by the excess of GH, and consequently increased insulin like growth factor 1 (IGF-1), are disproportionate growth of body parts, fluid retention, snoring and excessive perspiration. The various metabolic changes that occur due to acromegaly increase the risk for insulin resistance, diabetes mellitus, arterial hypertension, sleep apnoea and thus an increased risk of cardiovascular disease if left untreated. The result is signs and symptoms, increased mortality, morbidity, and greatly reduced quality of life (QoL). Normalisation of GH and IGF-1 gives a normalisation of mortality, however morbidity and QoL do not (completely) normalise. After surgery, a somatostatin analogue is the primary medical treatment, however, normalisation occurs in only 40% of patients.\n\nRecently, in a proof-of-principle study, the researchers showed that a 2-week ketogenic diet (low in carbohydrates) in patients with somatostatin analogues could significantly reduce IGF-1 values. Patients felt better and sometimes even needed less somatostatin analogues. This proof of concept led to the new hypothesis that acromegaly patients with somatostatin analogues should possibly be treated with a eucaloric low-carbohydrate ketogenic diet for a longer period of time to improve their biochemistry, symptoms and QoL. Additionally, this diet can make a significant contribution in the treatment of insulin resistance and glucose intolerance that often occur in this patient group.",[25,83,84],"Ketogenic Diet","Mediterranean Diet","2025-04-25",{"date":87,"type":36},"2025-04-29",{"date":89,"type":36},"2023-06-01",{"date":91,"type":21},"2028-05-01",{"name":93,"class":67},"Erasmus Medical Center"]